DGX
Quest Diagnostics Incorporated
NYSE: DGX · HEALTHCARE · DIAGNOSTICS & RESEARCH
$189.13
-0.90% today
Updated 2026-05-06
Market cap
$21.33B
P/E ratio
21.27
P/S ratio
1.89x
EPS (TTM)
$9.06
Dividend yield
1.68%
52W range
$162 – $213
Volume
0.9M
WallStSmart proprietary scores
63
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B5.3
Quality
C+6.0
Profitability
B4.7
Valuation
C2/9
Piotroski F-Score
Weak
2.3
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$223.12
+17.97%
12-Month target
$196.69
+4.00%
Intrinsic (DCF)
$166.17
Margin of safety
-25.97%
2 Strong Buy7 Buy9 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $164.00M — positive
Risks
- Piotroski 2/9 — weak financial health
- 25.97% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $9.88B | $9.25B | $9.87B | $11.04B | $11.28B | $11.9B |
| Net income | $946.00M | $854.00M | $871.00M | $992.00M | $252.00M | — |
| EPS | — | — | — | — | $9.06 | $10.74 |
| Free cash flow | $1.31B | $864.00M | $909.00M | $1.36B | $164.00M | — |
| Profit margin | 9.57% | 9.23% | 8.82% | 8.99% | 9.08% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-20 | SAMAD, SAM | Buy | 108 | $194.70 |
| 2026-04-20 | PLEWMAN, PATRICK | Buy | 49 | $194.70 |
| 2026-04-20 | LASSITER, WRIGHT III | Buy | 6 | $194.70 |
Peer comparison
Smart narrative
Quest Diagnostics Incorporated trades at $189.13. representing a P/E of 21.27x trailing earnings. Our Smart Value Score of 63/100 indicates the stock is good. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.29, it sits in the grey zone. TTM revenue stands at $11.28B. with profit margins at 9.08%. Our DCF model estimates intrinsic value at $166.17.
Frequently asked questions
What is Quest Diagnostics Incorporated's stock price?
Quest Diagnostics Incorporated (DGX) trades at $189.13.
Is Quest Diagnostics Incorporated overvalued?
Smart Value Score 63/100 (Grade C+, Hold). DCF value $166.17.
What is the price target of Quest Diagnostics Incorporated (DGX)?
The analyst target price is $223.12, representing +18.0% upside from the current price of $189.13.
What is the intrinsic value of Quest Diagnostics Incorporated (DGX)?
Based on our DCF model, intrinsic value is $166.17, a -26.0% margin of safety versus $189.13.
What is the future stock price of DGX by 2030?
Our research-backed model estimates Quest Diagnostics Incorporated could reach $1,504.95 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Quest Diagnostics Incorporated's revenue?
TTM revenue is $11.28B.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
2.29 — grey zone.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio1.89x
ROE14.50%
Beta0.65
50D MA$199.10
200D MA$186.41
Shares out0.11B
Float0.11B
Short ratio—
Avg volume0.9M
Performance
1 week+0.79%
1 month-4.10%
3 months+0.83%
YTD+9.96%
1 year—
3 years—
5 years—